In general, we unveil a novel pharmacological strategy for combating obesity-associated adipose tissue dysfunction by delineating a previously unrecognized mechanism through which ALM activates SIRT3 to orchestrate FUNDC1-mediated mitophagy. The gene discussed is FUNDC1; the disease is Obesity.